Clinical trials are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. HPVANDME reaches out to leading HPV cancer researchers to learn about current clinical trials that may help you and future HPV-related cancer patients. Please let these organizations know that you learned about the trial on HPV AND ME.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | SCREENING FOR HPV OROPHARYNGEAL CANCER
Human papillomavirus (HPV) causes many different types of cancers. In men, HPV-related throat cancer is on the rise, and there is currently no screening test (such as the Pap test used to detect HPV cervical cancer).
MD Anderson Cancer Center is conducting a trial called HOUSTON (HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men) to develop a test that can be used to screen for HPV-related throat cancer. Those who sign up will have access to tests that are not available to the general public.
This trial is open to men, ages 50-59. Learn more.
For questions or to enroll, email email@example.com or call 713-745-3511.
MASSACHUSETTS GENERAL HOSPITAL | IMMUNOTHERAPY SOLUTIONS
Dr. Sara Pai is currently an Associate Professor at Harvard Medical School and Massachusetts General Hospital and practices Otolaryngology-Head and Neck Surgery. For questions or to enroll, email Dr. Sara Pai.
CLINICAL TRIAL #1
A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
The clinical trial is studying drugs that can boost the participant’s immune system against the cancer cells as a possible treatment for head and neck cancer.
This trial is open to male and female patients with confirmed recurrent and/or metastatic head and neck cancer in the oral cavity, oropharynx, hypopharynx, or larynx — either HPV-positive or HPV-negative — who has progressed on anti-PD1, anti-PD-L1, anti-CTLA-4 or any other immune checkpoint blockade therapy. Learn more.
CLINICAL TRIAL #2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors
A 2013 study describes why HPV infects the tonsil as well as new therapies on how to reverse the immune system against the virus. The paper, Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma, is the basis of this clinical trial using anti-PD-1 for this patient population. PD-1 stands for “programmed cell death protein 1.” Therapies targeting PD-1 may augment immune responses to viruses such as HPV.
This trial is ongoing but is not currently recruiting participants. Learn more.